Amgen Inc
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen Later-Stage Clinical Programs by Year
Later-Stage Clinical Programs (Phase 2 & Phase 3 Trials) ($M) ($M)
Amgen Later-Stage Clinical Programs: $4,281M in FY2025, up 51.3% from a year earlier. That is the highest of the 13 years on record here.
Latest, FY2025
4,281
Period ended Dec 31, 2025
Change on a year earlier
+51.3%
2,830 in FY2024
History
13 years
Since FY2013
Sources
11
Documents cited below
Where the FY2025 figure comes from
“|| Later-Stage Clinical Programs | 4,281 | 2,830 | 1,898”
Source: Form 10-K (amgn-20251231.htm, filed 2026-02-13) ↗
Reported in Form 10-K Item 7 MD&A R&D Expense by Category Table.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Amgen Later-Stage Clinical Programs ($M), annual FY2013–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/rd-cat-later
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.